



**Protocol for Lucemyra® (lofexidine)  
Approved January 2022**

**Background:**

*Medically supervised opioid withdrawal, also known as detoxification, involves the administration of medication to reduce the severity of withdrawal symptoms that occur when an opioid-dependent patient stops using opioids*

*Lucemyra is a central alpha-2 adrenergic agonist indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults.*

**Criteria for Approval:**

Patient meets ALL the following:

1. Patient is  $\geq 18$  years old
2. Diagnosis of opioid use disorder
3. Patient is currently undergoing or is scheduled to undergo abrupt opioid discontinuation
4. Medication is prescribed by or in consultation with a provider specializing in pain management or addiction treatment
5. Patient has no history of congenital long QT syndrome; or will use Lucemyra with caution
6. Medication is prescribed in accordance with Food and Drug Administration (FDA) established indication and dosing regimens or in accordance with medically appropriate off-label indication and dosing according to American Hospital Formulary Service, Micromedex, Clinical Pharmacology, Wolters Kluwer Lexi-Drugs (Lexicomp), national guidelines, or other peer reviewed evidence

**Initial Approval:**

14 days per episode of treatment (224 total tablets)

**Dosing:**

Three 0.18 mg tablets taken orally four times daily for 7 days

Approvable for a maximum of 224 tablets per 14-day supply for a 1-month period

**Quantity Level Limit:**



Maximum dose 0.72 mg/dose (4 tablets) or 2.88 mg/day (16 tablets per day) or 224 tablets

**References:**

1. Lucemyra® [prescribing information]. US WorldMeds, LLC, 4441 Springdale Road, Louisville, KY 40241
2. Clinical Pharmacology® Gold Standard Series [Internet database]. Tampa FL. Elsevier 2019. Updated periodically
3. Sevarino KA. Medically supervised opioid withdrawal during treatment for addiction. UpToDate. Updated August 18, 2020. <https://www.uptodate.com/contents/medically-supervised-opioid-withdrawal-during-treatment-for-addiction> Accessed November 12, 2021